Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection

Figure 1 The treatment of patients with dual chronic hepatitis C/B and the durability of the hepatitis C virus response. A: Hepatitis C virus (HCV) sustained virologic response (SVR) rate at 6 mo after end of peg-interferon plus ribavirin combination treatment; B: Durability of HCV SVR in patients who initially obtained HCV SVR at 6 mo after end of therapy. Median 4.6-years (range: 1-5 years) post-treatment follow-up. SVR: Sustained virologic response; Peg-IFN: Peg-interferon; RBV: Ribavirin.